Boehringer: Pradaxa, Tradjenta launches face 'economic headwind'

Share this article:
Family-owned Boehringer Ingelheim chalked up some gains during the first six months of this year. Sales grew 6.8% compared to the same period last year, but the company warned this doesn't mean the next six months will be smooth. “The economic headwind from the sovereign debt crisis in southern Europe and the continued weak economic growth in the USA make the business environment increasingly difficult for the pharmaceutical industry,” Andreas Barner, chairman of the board, said in a statement.

Barner said that austerity measures are particularly hard on research-driven pharma companies, and noted that tighter wallets have made some countries so skittish that some are “wondering whether they can introduce new medications under their reduced healthcare and national budgets, even if these medications are clearly superior to standard treatment.”

Barner said the economic and financial chill have particularly affected the launches of blood thinner Pradaxa and diabetes medication Tradjenta. The company is highly dependent on its prescription drugs, which accounted for close to $7 billion in sales for the first six months of this year, a jump of 8.7% compared to the same period last year. The company's best-selling drug, Spiriva for COPD, accounted for $2.2 billion of these sales, while the Micardis hypertension franchise brought in $1.2 billion in sales. Pradaxa had $617 million in sales for the first six months of the year.

The company said North and South America remain its hot markets, accounting for almost $4 billion in sales for the first half of 2012, a 9.5% jump compared to the sales for the same period last year.

Finance head Hubertus von Baumbach said in a statement that the company has been performing as expected, but also echoed Barner's caution, saying “sustaining the positive business development in the first half of 2012 over the next six months will be challenging.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...